

Overview | Current ACT-A priorities for 2021



Deploy what we have



Prepare for what's coming



Enrich research pipeline



Inpatients

(Severe & Critical cases)

Drive uptake of the very effective care package we already have

Outpatients

(Mild, Moderate & PEP)

Ensure country readiness for the promising products currently in Ph.3 trials



R&D pipeline

(all use cases with OP emphasis)

Enrich research pipeline, facilitate novel and combination treatment

Deploy what we have I/II | Driving uptake of the inpatient care package we already have







Guidelines

Reviewing guidance & developing operational guidance to ensure easier uptake

Technical support

Ensure availability of technical coordination for countries in need (to enable development of treatment strategy)

Accelerate access

Accelerate access through C19RM fasttrack requests, and ensure support during surges, leveraging the partnership

(deep-dive overleaf)





Deploy what we have II/II

The Oyxgen
Taskforce is
pushing on
targeted actions
to deploy the
inpatient care
package that is
already available



Technical Cooperation partner support in >40 countries



>US\$ 210m C19RM Oxygen requests approved so far for 27 countries¹



MoUs signed with liquid O₂ manufacturers, with a first deal agreed for Zambia




Prepare for what's coming

9 outpatient products in Ph.3 trials likely to read out by end of year, that we need to prepare for by...



Scaling testing in countries



Ensuring country readiness (e.g. Unitaid/FIND RFP, allocation

criteria, engagement and visibility on country-specific plans, demand creation)



Being ready for procurement fund needs in Q4 or early '22